Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain TSRO message board posts where the ticker symbol TSRO has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest TSRO SEC Filings

Filings Format Description Filing Date File/Film Number
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001104659-18-032566 Size: 11 KB
2018-05-11
8-K  Documents Current report, items 5.02, 5.07, and 9.01
Acc-no: 0001104659-18-032563 (34 Act)  Size: 78 KB
2018-05-11 001-35587
18827580
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001558370-18-003902 (34 Act)  Size: 6 MB
2018-05-03 001-35587
18804398
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001104659-18-030252 (34 Act)  Size: 206 KB
2018-05-03 001-35587
18803813
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-18-004828 (34 Act)  Size: 11 KB
2018-04-16 001-35587
18756135
DEF 14A  Documents Other definitive proxy statements
Acc-no: 0001047469-18-002618 (34 Act)  Size: 1 MB
2018-04-06 001-35587
18743302
8-K  Documents Current report, item 7.01
Acc-no: 0001104659-18-018769 (34 Act)  Size: 21 KB
2018-03-20 001-35587
18700665
8-K  Documents Current report, item 7.01
Acc-no: 0001104659-18-017320 (34 Act)  Size: 23 KB
2018-03-14 001-35587
18688387
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001104659-18-016393 Size: 4 KB
2018-03-09
SC 13D/A  Documents [Amend] General statement of acquisition of beneficial ownership
Acc-no: 0001072613-18-000199 (34 Act)  Size: 454 KB
2018-03-09 005-86904
18679941
More TSRO SEC Filings


Related news from
Wed, 23 May 2018
12:00:00 +0000
Today's Research Reports on Trending Tickers: Tesaro and Exelixis
NEW YORK, NY / ACCESSWIRE / May 23, 2018 / U.S. markets fell Tuesday on geopolitical concerns after President Trump stated he was not happy with the current U.S. – China trade talks. The Dow Jones Industrial ...
Wed, 23 May 2018
01:15:00 +0000
Is This Stock the Next Biotech Acquisition Target?
Optimism is growing that this cancer drug developer will be the next biotech to be acquired.
Tue, 22 May 2018
17:18:46 +0000
Analyzing Tesaro’s Financial Performance
Tesaro (TSRO) generated total revenues of $49.7 million in the first quarter—compared to $3 million in the first quarter of 2017. Tesaro’s licensing and collaboration revenues were $934,000 in the first quarter of 2017. The change was due to a $1 million reversal of milestone payments recognized by Tesaro in 2015 and 2016 from the Hengrui license agreement. Tesaro concluded that the agreement probably wouldn’t be achieved.
Tue, 22 May 2018
17:18:46 +0000
How Are Tesaro’s Valuations and Cash Flows?
Tesaro used $147.6 million in operating activities in the first quarter—compared to $114.6 million in the first quarter of 2017. The company used $1.6 million in investing activities in the first quarter—compared to $1.8 million in the first quarter of 2017. The expense was mainly for purchasing property and equipment related to Tesaro expanding leased premises at its headquarters.
Tue, 22 May 2018
17:18:45 +0000
Tesaro’s Zejula Promises Significant Growth
Tesaro’s (TSRO) products on the market are Zejula and Varubi. Zejula has been approved in the United States and the European Union as a maintenance treatment for adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Varubi has been approved in the United States and the European Union in combination with other antiemetic agents in adults to prevent delayed nausea and vomiting associated with chemotherapy.
Tue, 22 May 2018
17:18:45 +0000
Tesaro Stock: What’s the Upside Potential?
Tesaro (TSRO) is a commercial stage biopharmaceutical company focused on developing treatments for solid tumors. Tesaro is licensed and developing a number of oncology-related product candidates. Of the 19 analysts covering Tesaro in May, 12 analysts gave the stock a “buy” or higher rating, while seven analysts gave a “hold” rating.
Tue, 22 May 2018
15:23:17 +0000
How Confident Are Insiders About Tesaro Inc (NASDAQ:TSRO)?
Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. Tesaro’s insiders have invested 150,532 shares in theRead More...
Mon, 21 May 2018
11:25:00 +0000
Stock Performance Review on Tesaro and Three Other Biotech Industry
LONDON, UK / ACCESSWIRE / May 21, 2018 / If you want a free Stock Review on TSRO sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Surface Oncology Inc. (SURF), Synthetic Biologics Inc. (NYSE AMER: SYN), Teligent Inc. (NASDAQ: TLGT), Tesaro Inc. (NASDAQ: TSRO).
Wed, 16 May 2018
21:15:00 +0000
TESARO Announces Presentations of Abstracts at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Investor briefing to be webcast from Chicago on Monday, June 4, 2018 at 6:15PM CT WALTHAM, Mass., May 16, 2018-- TESARO, Inc., an oncology-focused biopharmaceutical company, today announced the presentation ...
Mon, 14 May 2018
11:31:02 +0000
How Lynparza Performed in 1Q18
On July 27, Merck (MRK) and AstraZeneca (AZN) announced a strategic global collaboration for co-developing and co-commercializing the latter’s poly ADP ribose polymerase (or PARP) inhibitor, Lynparza. In 1Q18, Merck reported $33 million as its share of the Lynparza alliance revenues, of which $24 million were earned in US markets, while the remaining $9.0 million were reported from international markets. Lynparza is currently the leading PARP inhibitor in terms of new and total prescriptions for its approved label in ovarian cancer and breast cancer indications.
Thu, 10 May 2018
19:23:37 +0000
Former Biotech Darlings Tesaro, Clovis Pin Hopes on 2018 Rebound
Considered a year ago to be among the top takeover targets in biotech, Tesaro Inc. and Clovis Oncology Inc. have so far failed to live up to their hype on Wall Street. Shares of Tesaro have fallen 71 percent since the U.S. Food and Drug Administration approved its ovarian cancer drug Zejula in March 2017. Clovis is down 32 percent over that time as its competing therapy has also struggled to meet sales estimates.
Wed, 09 May 2018
18:27:31 +0000
With A -24.35% Earnings Drop, Is Tesaro Inc’s (NASDAQ:TSRO) A Concern?
When Tesaro Inc (NASDAQ:TSRO) released its most recent earnings update (31 March 2018), I wanted to understand how these figures stacked up against its past performance. The two benchmarks IRead More...
Tue, 08 May 2018
13:25:05 +0000
Psychological Effects of Ovarian Cancer Often Overlooked and Can Have a Significant Impact on Patients
TESARO, Inc., an oncology-focused biopharmaceutical company, today announced results from a TESARO-sponsored Europe-wide literature review examining the views of both patients and physicians on the communication and treatment needs in the care of women with ovarian cancer. The comprehensive review confirms that the psychosocial effects of ovarian cancer play a significant part in a woman`s quality of life.  The review, `Our Way Forward - Ovarian Cancer in Europe` draws data from approximately 65 publications and patient surveys, spanning the last 15 years. The `Our Way Forward - Ovarian Cancer in Europe` literature review is part of TESARO`s commitment to ovarian cancer as exemplified by the Our Way Forward program, an initiative that was launched in the U.S. last year.  The review is the first step towards supporting the development of patient-focused information tools and bringing the debate in ovarian cancer higher up the medical and political agenda.
Mon, 07 May 2018
10:10:22 +0000
Edited Transcript of TSRO earnings conference call or presentation 3-May-18 8:15pm GMT
Q1 2018 TESARO Inc Earnings Call
Fri, 04 May 2018
12:16:46 +0000
Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on May 3) ABIOMED, Inc. (NASDAQ: ABMD ) (reported better-than-expected ...
Thu, 03 May 2018
21:40:20 +0000
Tesaro Dives After First-Quarter Sales Lag On Wider-Than-Expected Losses
Tesaro on Thursday reported a loss of $2.98 per share on $49.7 million in revenue for its first quarter.
Thu, 03 May 2018
20:41:10 +0000
Tesaro: 1Q Earnings Snapshot
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of $2.98. The results fell short of Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment ...
Thu, 03 May 2018
20:05:00 +0000
TESARO Announces First-Quarter 2018 Operating Results
ZEJULA Q1 net sales totaled $49 million Enrollment completed in Phase 3 PRIMA first-line ovarian cancer monotherapy trial TOPACIO platinum-resistant ovarian cancer and triple-negative breast cancer data ...
Tue, 01 May 2018
20:15:00 +0000
TESARO Announces Participation in Two Investor Conferences
WALTHAM, Mass., May 01, 2018-- TESARO, Inc., an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The Bank of America Merrill Lynch 2018 ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "VF is the place to be to pick up on new and proven investment ideas." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards